SCLX vs. MKTW, PRME, RGNX, CRGX, ITOS, HLVX, VALN, TSHA, KYTX, and EXAI
Should you be buying Scilex stock or one of its competitors? The main competitors of Scilex include MarketWise (MKTW), Prime Medicine (PRME), REGENXBIO (RGNX), CARGO Therapeutics (CRGX), iTeos Therapeutics (ITOS), HilleVax (HLVX), Valneva (VALN), Taysha Gene Therapies (TSHA), Kyverna Therapeutics (KYTX), and Exscientia (EXAI).
MarketWise (NASDAQ:MKTW) and Scilex (NASDAQ:SCLX) are both small-cap business services companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, community ranking, institutional ownership, media sentiment, earnings, dividends, profitability, valuation and risk.
MarketWise has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500. Comparatively, Scilex has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500.
MarketWise has higher revenue and earnings than Scilex. Scilex is trading at a lower price-to-earnings ratio than MarketWise, indicating that it is currently the more affordable of the two stocks.
MarketWise has a net margin of 0.46% compared to MarketWise's net margin of -229.47%. MarketWise's return on equity of 0.00% beat Scilex's return on equity.
MarketWise received 21 more outperform votes than Scilex when rated by MarketBeat users. However, 100.00% of users gave Scilex an outperform vote while only 65.00% of users gave MarketWise an outperform vote.
In the previous week, Scilex had 6 more articles in the media than MarketWise. MarketBeat recorded 8 mentions for Scilex and 2 mentions for MarketWise. Scilex's average media sentiment score of 0.62 beat MarketWise's score of -0.19 indicating that MarketWise is being referred to more favorably in the media.
23.0% of MarketWise shares are held by institutional investors. Comparatively, 69.7% of Scilex shares are held by institutional investors. 28.6% of MarketWise shares are held by insiders. Comparatively, 8.7% of Scilex shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
MarketWise currently has a consensus price target of $3.50, indicating a potential upside of 169.23%. Scilex has a consensus price target of $5.50, indicating a potential upside of 409.26%. Given MarketWise's stronger consensus rating and higher probable upside, analysts clearly believe Scilex is more favorable than MarketWise.
Summary
MarketWise beats Scilex on 9 of the 17 factors compared between the two stocks.
Get Scilex News Delivered to You Automatically
Sign up to receive the latest news and ratings for SCLX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SCLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
